Joseph Leveque, MD, is President, Chief Medical Officer, and a Board Member of Medikine.

Joe has over a decade’s worth of experience in the development of immune-oncology therapeutics. Most recently, Joe was Executive Vice President and Chief Medical Officer of Mirati Therapeutics, Inc. (Nasdaq:MRTX), where he was responsible for leading the clinical development of their portfolio of selective KRAS inhibitors and other small molecules for cancer therapy. Prior to Mirati, he served as Chief Medical Officer of Synthorx, a company focused on the application of synthetic biology in the discovery and development of cytokines that was acquired by Sanofi in late 2019. Prior to Synthorx, he served as Chief Medical Officer at ARMO Biosciences, a late-stage immuno-oncology company that was acquired by Eli Lilly in May 2018. Prior to these roles, Joe was Chief Medical Officer of EMD Serono, the North American subsidiary of Merck KGaA, and Vice President and Head of US Medical Oncology at Bristol-Myers Squibb, where he was part of the team developing and commercializing the first generation of immuno-oncology therapeutics. He has also held key medical leadership positions at Onyx Pharmaceuticals, Cephalon Oncology, and Amgen. Joe received a BS in Biology and Mathematics from Santa Clara University, an MBA from the Wharton School of the University of Pennsylvania, and an MD from The University of Texas School of Medicine in Houston, TX. He completed his post-graduate medical training in internal medicine at the Cedars-Sinai Medical Center, a teaching affiliate of the University of California, Los Angeles (UCLA).

Medikine, Inc. is a preclinical development-stage biopharmaceutical company focused on the discovery and development of peptide-based agonists of heterodimeric receptors for clinically relevant cytokines. Medikine’s peptide-based agonists have unique advantages over cytokine modification approaches. The company recently completed a $32M Series A financing led by Samsara Biocapital.

Soojin Kim, Ph.D. appointed SVP/Chief Technology Operations Officer at Inozyme Pharma, Boston, MA

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency.

Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University.

Lengo Therapeutics Acquired

Blueprint Medicines Completes Acquisition of Lengo Therapeutics…Expands Blueprint Medicines’ lung cancer pipeline with LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations. Investigational New Drug application for LNG-451 submitted to U.S. FDA by Lengo Therapeutics in December.